Cargando…

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases

Although the development of new antifibrotic agents (pirfenidone, nintedanib) has modified the disease progression of idiopathic pulmonary fibrosis (IPF), there is still no effective treatment for acute exacerbation of interstitial lung diseases (ILD) including IPF. We herein report a case of acute...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Yoko, Tazaki, Gen, Kondo, Yusuke, Takahashi, Genki, Sakamaki, Fumio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409392/ https://www.ncbi.nlm.nih.gov/pubmed/30931251 http://dx.doi.org/10.1016/j.rmcr.2019.02.021

Ejemplares similares

Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world
por: Kato, Motoyasu, et al.
Publicado: (2023)

Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases
por: Nakashima, Kazuki, et al.
Publicado: (2021)

Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan
por: Urushiyama, Hirokazu, et al.
Publicado: (2022)

Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
por: Tomioka, Hiromi, et al.
Publicado: (2017)

Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Nintedanib induces gene expression changes in the lung of induced-rheumatoid arthritis–associated interstitial lung disease mice
por: Mikami, Shintaro, et al.
Publicado: (2022)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease
por: Vacchi, Caterina, et al.
Publicado: (2020)

Suppression of epithelial abnormalities by nintedanib in induced-rheumatoid arthritis-associated interstitial lung disease mouse model
por: Miura, Yoko, et al.
Publicado: (2021)

Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis‐associated interstitial lung disease
por: Sumi, Toshiyuki, et al.
Publicado: (2021)

Acute Exacerbation in Interstitial Lung Disease
por: Leuschner, Gabriela, et al.
Publicado: (2017)

Acute exacerbation in interstitial lung disease
por: Alhamad, Esam H., et al.
Publicado: (2021)

An Autopsy Case of Paradoxical Pulmonary Thromboembolism by Arteriovenous Fistula from Right Common Iliac Artery to Common Iliac Vein: A Rare Cause of Pulmonary Embolism
por: Takahashi, Fuminari, et al.
Publicado: (2018)

Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
por: Schmid, Ulrike, et al.
Publicado: (2021)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Pulmonary perfusion by chest digital dynamic radiography: Comparison between breath‐holding and deep‐breathing acquisition
por: Yamamoto, Shota, et al.
Publicado: (2020)

Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
por: Shimomura, Iwao, et al.
Publicado: (2018)

Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies
por: Yanagihara, Toyoshi, et al.
Publicado: (2020)

Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
por: Toellner, Hannah, et al.
Publicado: (2017)

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
por: Westerink, Lotte, et al.
Publicado: (2022)

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
por: Bonella, Francesco, et al.
Publicado: (2022)

A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib
por: Kakuwa, Tamaki, et al.
Publicado: (2018)

Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report
por: Ikeda, Satoshi, et al.
Publicado: (2016)

Fatal diffuse alveolar haemorrhage mimicking acute exacerbation in idiopathic pulmonary fibrosis treated with nintedanib
por: Sugino, Keishi, et al.
Publicado: (2017)

Combined ultrasound–CT approach to monitor acute exacerbation of interstitial lung disease
por: Mongodi, Silvia, et al.
Publicado: (2020)

COVID-19 and acute exacerbation of interstitial lung disease
por: Kondoh, Yasuhiro, et al.
Publicado: (2021)

Acute exacerbations of progressive-fibrosing interstitial lung diseases
por: Kolb, Martin, et al.
Publicado: (2018)

Acute Exacerbations of Interstitial Lung Diseases: Focus on Biomarkers
por: Drakopanagiotakis, Fotios, et al.
Publicado: (2023)

Comment on: Combination of immunosuppressive therapy and nintedanib improves capillaroscopic changes in systemic sclerosis–interstitial lung disease: a case report
por: Sugimoto, Tomohiro, et al.
Publicado: (2022)

Combination of immunosuppressive therapy and nintedanib improves capillaroscopic changes in systemic sclerosis-interstitial lung disease: a case report
por: Matsuda, Shogo, et al.
Publicado: (2022)

Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug
por: Kafle, Sunam, et al.
Publicado: (2021)

Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort?
por: Ho, Gen Nen, et al.
Publicado: (2023)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe
por: Kaushal, Mohit, et al.
Publicado: (2022)

Acute exacerbations of interstitial lung disease: what is the best treatment?
por: Meyer, Keith C.
Publicado: (2021)

Acute exacerbation of interstitial lung disease in the intensive care unit
por: Charokopos, Antonios, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jmok2gv4ja9q4j4k65995jn2mb